ST Pharm Co.,Ltd. (KOSDAQ:237690)
143,300
+2,200 (1.56%)
Apr 10, 2026, 3:30 PM KST
ST Pharm Revenue
In the year 2025, ST Pharm had annual revenue of 331.68B KRW with 21.16% growth. ST Pharm had revenue of 129.10B in the quarter ending December 31, 2025, with 11.55% growth.
Revenue
331.68B
Revenue Growth
+21.16%
P/S Ratio
8.86
Revenue / Employee
506.38M
Employees
655
Market Cap
2.94T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 331.68B | 57.93B | 21.16% |
| Dec 31, 2024 | 273.75B | -11.24B | -3.94% |
| Dec 31, 2023 | 284.99B | 35.67B | 14.31% |
| Dec 31, 2022 | 249.32B | 83.68B | 50.52% |
| Dec 31, 2021 | 165.64B | 41.53B | 33.47% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4.56T |
| Celltrion | 4.16T |
| Samsung Epis Holdings | 3.02T |
| Hanmi Science | 1.36T |
| SK bioscience | 651.37B |
| PharmaResearch | 536.29B |
| Hugel | 425.11B |
| ALTEOGEN | 215.86B |